<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544932</url>
  </required_header>
  <id_info>
    <org_study_id>PREFER-AF</org_study_id>
    <nct_id>NCT02544932</nct_id>
  </id_info>
  <brief_title>Pleotropic Effect of New Oral Anticoagulants</brief_title>
  <official_title>Prospective Randomized Study for Evaluating Vascular Protective Effects of New Oral Anticoagulants in High Risk Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including&#xD;
      endothelial dysfunction of heart and vessel. This study was designed to determine the&#xD;
      efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of&#xD;
      atherosclerosis of AF subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The properties of oral, direct inhibitors of factor Xa (e.g. rivaroxaban) and thrombin (e.g.&#xD;
      dabigatran) have been examined the haemostasis and thromboembolism management. Preclinical&#xD;
      studies have provided evidences for the effects of direct factor Xa or thrombin inhibition&#xD;
      beyond anticoagulation, including anti-inflammatory and protective activities in&#xD;
      atherosclerotic plaque development . Therefore, this study evaluates the protective effects&#xD;
      of NAOC with the reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements&#xD;
      reflecting endothelial function by Endo-PAT2000 and intima-media thickness (IMT) of the&#xD;
      carotid artery, which is used as a surrogate endpoint of atherosclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes in reactive hyperemia index (RHI)</measure>
    <time_frame>12months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>right and left maximum IMT of the common carotid artery (CCA)</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>right and left mean IMT of the common carotid artery (CCA)</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>24months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>dabigatran 110mg or 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ribaroxaban 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months</description>
    <arm_group_label>dabigatran 110mg or 150mg</arm_group_label>
    <other_name>pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribaroxaban</intervention_name>
    <description>After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.</description>
    <arm_group_label>ribaroxaban 20mg</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.</description>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CHA2DS2-VASc score above 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe peripheral arterial disease (greater than a Fontaine IIb category)&#xD;
&#xD;
          -  grade 4 or higher cerebral infarction on the Modified Rankin Scale&#xD;
&#xD;
          -  proven coronary artery disease by coronary angiogram&#xD;
&#xD;
          -  severe hepatic or renal dysfunction&#xD;
&#xD;
          -  uncontrolled congestive heart failure&#xD;
&#xD;
          -  uncontrolled hypertension or diabetes mellitus&#xD;
&#xD;
          -  hematologic disorders&#xD;
&#xD;
          -  allergy or hypersensitivity to the investigational drugs&#xD;
&#xD;
          -  pregnant or lactating women or women wishing to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weon Kim, MD, PhD</last_name>
    <phone>82-2-958-8170</phone>
    <email>mylovekw@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin-Bae Kim, MD, PhD</last_name>
    <phone>82-2-958-8167</phone>
    <email>jinbbai@khu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyung Hee University</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Weon Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>endothelium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

